Fate Therapeutics recently announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation for the lupus treatment candidate FT819.

Approximately 15% to 30% of patients have lupus nephritis at the time of SLE diagnosis, with more patients at risk of developing lupus nephritis over the course of their disease. An estimated 30% ...

The cell and gene therapy company is cutting 47 employees and its entire lupus program to focus resources on two CAR Ts. The ...

Early Diagnosis and Monitoring of Lupus Nephritis -- On Your Smartphone Feb. 1, 2023 — A pair of researchers reports the success of their new, at-home method for early diagnosis and monitoring ...

The following is a summary of “Factors associated with worsening interstitial fibrosis/tubular atrophy in lupus nephritis ...

Fate Therapeutics FATE recently announced that the FDA has granted the Regenerative Medicine Advanced Therapy (RMAT) ...

The systematic review and meta-analysis ultimately included 57 studies evaluating patients with SLE who received one of three different types of renal replacement therapy due to lupus nephritis.

WASHINGTON -- Lupus nephritis (LN) diagnosis could improve greatly if early results with a multimarker urine test are confirmed in larger studies, research presented here suggested. Measurement of ...